De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CareDx Toekomstige groei

Future criteriumcontroles 1/6

De verwachting is dat CareDx de winst en omzet met respectievelijk 84% en 10% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 84.8% per jaar.

Belangrijke informatie

84.0%

Groei van de winst

84.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.8%
Inkomstengroei	10.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	26 Sep 2024

Recente toekomstige groei-updates

Recent updates

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

Sep 29

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Aug 01

CareDx: Benefiting From Some Certainty

Jul 15

Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge

Apr 27

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Mar 02

CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 27

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27

Winst- en omzetgroeiprognoses

NasdaqGM:CDNA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	388	-14	N/A	N/A	5
12/31/2025	347	-37	N/A	36	8
12/31/2024	325	-42	N/A	22	8
6/30/2024	297	-160	-22	-15	N/A
3/31/2024	275	-183	-42	-34	N/A
12/31/2023	280	-190	-28	-18	N/A
9/30/2023	297	-91	-14	-3	N/A
6/30/2023	309	-84	-14	0	N/A
3/31/2023	320	-81	-22	-3	N/A
12/31/2022	322	-77	-50	-25	N/A
9/30/2022	319	-74	-55	-28	N/A
6/30/2022	315	-69	-45	-21	N/A
3/31/2022	308	-50	-34	-7	N/A
12/31/2021	296	-31	-40	-19	N/A
9/30/2021	276	-18	-31	-16	N/A
6/30/2021	254	-9	-27	-11	N/A
3/31/2021	221	-14	-8	3	N/A
12/31/2020	192	-19	23	33	N/A
9/30/2020	169	-20	14	25	N/A
6/30/2020	150	-19	13	21	N/A
3/31/2020	139	-20	-4	0	N/A
12/31/2019	127	-22	-6	-3	N/A
9/30/2019	115	-21	-3	0	N/A
6/30/2019	102	-39	-3	0	N/A
3/31/2019	88	-45	-13	-5	N/A
12/31/2018	77	-47	-11	-4	N/A
9/30/2018	66	-75	-15	-8	N/A
6/30/2018	57	-69	-17	-11	N/A
3/31/2018	51	-59	N/A	-12	N/A
12/31/2017	48	-55	N/A	-14	N/A
9/30/2017	47	-39	N/A	-15	N/A
6/30/2017	47	-29	N/A	-14	N/A
3/31/2017	46	-35	N/A	-17	N/A
12/31/2016	41	-39	N/A	-17	N/A
9/30/2016	36	-29	N/A	-17	N/A
6/30/2016	31	-28	N/A	-19	N/A
3/31/2016	27	-21	N/A	-15	N/A
12/31/2015	28	-14	N/A	-10	N/A
9/30/2015	29	-9	N/A	-6	N/A
6/30/2015	29	-4	N/A	-7	N/A
3/31/2015	29	0	N/A	-5	N/A
12/31/2014	27	1	N/A	-3	N/A
9/30/2014	25	0	N/A	-4	N/A
6/30/2014	24	-2	N/A	2	N/A
3/31/2014	23	-3	N/A	1	N/A
12/31/2013	22	-4	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CDNA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CDNA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CDNA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CDNA ( 10% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van CDNA ( 10% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CDNA naar verwachting over 3 jaar hoog zal zijn

CareDx Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

CareDx, Inc Revises Earnings Guidance for the Full Year 2024

Price target increased by 11% to US$14.40

CareDx, Inc Provides Revenue Guidance for the Full Year of 2024

CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023

Price target increased by 11% to US$11.80

Price target decreased by 16% to US$10.80

Recent updates

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

CareDx, Inc Appoints Keith Kennedy as Chief Operating Officer

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

CareDx, Inc Revises Earnings Guidance for the Full Year 2024

CareDx, Inc to Report Q2, 2024 Results on Jul 31, 2024

CareDx: Benefiting From Some Certainty

CareDx, Inc Announces New Data to Be Presented At the 2024 American Transplant Congress

Study Shows CareDx, Inc.’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

Price target increased by 11% to US$14.40

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Executive Director exercised options to buy US$123k worth of stock.

CareDx, Inc, Annual General Meeting, Jun 13, 2024

Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge

CareDx, Inc Appoints John W. Hanna as Chief Executive Officer

CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS misses analyst expectations

CareDx, Inc Provides Revenue Guidance for the Full Year of 2024

CareDx, Inc to Report Q4, 2023 Results on Feb 28, 2024

Jury Rules in Favor of Natera, Inc in Patent Infringement Lawsuit Against CareDx, Inc

CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023

Price target increased by 11% to US$11.80

CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

CareDx, Inc to Report Q3, 2023 Results on Nov 08, 2023

CareDx, Inc Announces Resignation of Reginald Seeto as Chief Executive Officer

CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents

CareDx, Inc Announces Executive Changes

SEC Concludes Investigation as to CareDx and Does Not Intend to Recommend an Enforcement Action

Price target decreased by 16% to US$10.80

Consensus EPS estimates fall by 14%

Independent Director exercised options to buy US$173k worth of stock.

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CareDx, Inc. Provides Revenue Guidance for the Full Year 2023

CareDx, Inc to Report Q2, 2023 Results on Aug 08, 2023

CareDx, Inc. Announces Medicare Coverage for HeartCare

Price target increased by 26% to US$12.60

CareDx, Inc (NasdaqGM:CDNA) acquired MediGO, Inc.

CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring

New minor risk - Share price stability

President notifies of intention to sell stock

Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price

Consensus revenue estimates fall by 13%

Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CareDx, Inc to Report Q1, 2023 Results on May 10, 2023

Consensus EPS estimates fall by 10%

Price target decreased by 22% to US$20.40

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

CareDx, Inc. Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions At the 2023 Tandem Meetings

Executive Director notifies of intention to sell stock

Executive Director notifies of intention to sell stock

Price target decreased by 7.6% to US$26.17

CareDx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

President notifies of intention to sell stock

Executive Officer notifies of intention to sell stock

CareDx, Inc (NasdaqGM:CDNA) announces an Equity Buyback for $50 million worth of its shares.

CareDx, Inc Announces the Results of A New Study Published in Transplantation Direct

CareDx, Inc Announces Resignation of Ralph Snyderman as Director, Effective from December 31, 2022

Price target decreased to US$30.00

Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.23 loss in 3Q 2021)

Caredx, Inc., Revises Revenue Guidance for the Full Year 2022

Independent Longitudinal Study Finds Caredx’S Allosure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

CareDx, Inc to Report Q3, 2022 Results on Nov 03, 2022

CareDx: Shaking Off First-Mover Disadvantage

Caredx, Inc Announces Transplant Patients Experience Less Pain and Fewer Adverse Events with Caredx Non-Invasive Testing Solutions

CareDx, Inc Announces Executive Changes